was sent to J. Nicolet, University of Bern, Bern, Switzerland, or to R. Nielsen, State Veterinary Serum Laboratory, Copenhagen, Denmark, for definite serotyping.
In addition to the A. pleuropneumoniae strains, we tested A. suis type strain NCTC 10840 and four Dutch A. suis field strains. The strains were classified phenotypically (3) and differed from A. pleuropneumoniae biotype 2 in a positive test result for esculin, salicin, trehalose, and growth on MacConkey agar and a negative test result for mannitol.
Toxin-containing culture filtrates were obtained as described by Frey and Nicolet (9) , and each filtrate was tested for the presence of Apx toxins with each of the MAbs CVI-Apcly 2.2, 9.1, 9.2, 9.3, and 9.4 (14) in a dot blot assay according to the recommendations of the manufacturer of the dot blot apparatus (Bio-Rad, Richmond, Calif.). The molecular masses of the proteins that reacted with the MAbs were determined by Western blot (immunoblot) analysis (14) of 10-fold-concentrated culture filtrates with a mixture of the five MAbs. Culture filtrates of the reference strains of biotype 1, serotypes 8 and 11, were used as references.
Each filtrate was further tested for hemolytic (9) and cytotoxic (15) activities. A filtrate was defined as strongly hemolytic when it totally hemolyzed erythrocytes and as weakly hemolytic when it only partially hemolyzed erythrocytes and hemolysis could not be read with the naked eye. A filtrate was defined as strongly cytotoxic when it had a titer of .64 and as moderately cytotoxic when it had a titer of c32.
Filtrates of all strains but one belonging to biotype 1, serotypes 1, 5, 9, and 11, reacted in the dot blot assay with all MAbs against ApxI and ApxII, and Western blot analysis revealed two proteins that comigrated with ApxI and ApxII. All filtrates were strongly hemolytic and strongly cytotoxic. We concluded that these strains produced ApxI and ApxII ( Table  2 ). The one exception was a serotype 9 strain from Australia, which produced ApxII only ( Table 2) .
Filtrates of all strains but one belonging to biotype 1, serotypes 2, 3, 6, and 8, reacted in the dot blot assay with all MAbs against ApxII and ApxIII, and Western blot analysis revealed two proteins that comigrated with ApxII and ApxIII. All of these filtrates were weakly hemolytic and strongly cytotoxic. We concluded that these strains produced ApxII and ApxIII ( Table 2 ). The one exception was a serotype 2 strain from Australia, which produced ApxII only ( Table 2) .
Filtrates of all strains but two belonging to biotype 1, serotypes 7 and 12, and of all strains belonging to biotype 2, serotypes 1 and 2, reacted in the dot blot assay with the MAbs against ApxII only, and Western blot analysis revealed one protein that comigrated with ApxII. The filtrates were weakly hemolytic and moderately cytotoxic. We concluded that these strains produced ApxII ( Table 2 ). The two exceptions were two biotype 1, serotype 7, strains from The Netherlands, which produced ApxII and ApxIII ( Table 2) .
Filtrates of all strains belonging to biotype 1, serotype 10, reacted in the dot blot assay with the MAbs against ApxI only, and Western blot analysis revealed one protein that comigrated with ApxI. These filtrates were strongly hemolytic and strongly cytotoxic. We concluded that these strains produced ApxI ( Table 2) .
Filtrates of the A. suis strains reacted in the dot blot assay with all MAbs against ApxI and ApxII, and Western blot analysis revealed two proteins that comigrated with ApxI and ApxII (Fig. 1) ; the filtrates were strongly hemolytic and strongly cytotoxic. We concluded that these strains produced proteins similar to ApxI and ApxII.
To determine whether the field strains produced cytolytic proteins other than those produced by the reference strains of A. pleuropneumoniae, each filtrate was tested in a cytotoxin neutralization assay with a serum against crude Apx toxins of A. pleuropneumoniae reference strains (15 (11) . However,A. suis produces an RTX toxin which is identical to ApxII even at the amino acid level (2) . In this study, we confirmed that A. suis strains produce a toxin similar to ApxII, but we also found thatA. suis produces a toxin similar to ApxI. We therefore assume that serological tests based on ApxI, ApxII, or both will detect infections not only with A. pleuropneumoniae but also with A. The Apx toxins are essential components in protective vaccines (10) . Whether a vaccine of the toxins alone will be sufficient for protection is not clear yet; data published so far on vaccination with purified Apx toxins are inconclusive (4, 22) . In this study, we found no cytolytic proteins other than ApxI, -II, and -III. Hence, incorporation of ApxI, -II, and -III into a vaccine may protect pigs against challenge with any A. pleuropneumoniae strain. This hypothesis is supported by our findings that a mixture of culture filtrates of serotypes 3 and 9 protected pigs against challenge with homologous and heterologous serotypes (16) .
In a previous study in which we identified the three cytolytic proteins among the serotype reference strains of A. pleuropneumoniae, we reported that the reference strain of serotype 6 produced ApxII only (14) . While examining field strains of serotype 6, we found that we had the wrong strain as the reference for serotype 6 . Consequently, the data we have published on serotype 6 are incorrect (13) (14) (15) . Strain Femo, which is the reference strain for serotype 6, produces ApxII and ApxIII. The strain we used as a reference for serotype 6 may represent a new serotype. Antiserum raised against this strain does not agglutinate any other serotype reference strain, and the strain does not agglutinate in antisera raised against the other A. pleuropneumoniae serotypes.
